Senescent-Cell Clearance
Clear the worn-out cells that drive aging and disease
The goal is to clear the worn-out “senescent” cells that accumulate with age — cells that no longer work but won’t die, and that poison the tissue around them — to reduce age-related decline. We pursue it seriously and hold it to a high evidence bar, because this field attracts hype.
As we age, some cells stop dividing but refuse to die, becoming senescent. They linger and release signals that inflame and damage surrounding tissue, contributing to many age-related diseases. Because these cells are a shared driver of aging, clearing them could address multiple conditions at once. It is one of the most studied mechanisms inside healthspan extension — and one of the easiest to overhype, so we are deliberately careful here.
We are building the capability to selectively remove senescent cells and calm the damage they cause: clearing them with targeted therapies, reducing the inflammation they drive, and doing so safely and precisely — aiming to add healthy years, honestly measured.
Removing the cells that drive decline
Clearing senescent cells In human trials
Drugs called senolytics selectively clear senescent cells; in animals they reversed multiple signs of aging, and they are now being tested in human trials.
Calming the damage they cause Clinical
Reducing the inflammatory signals senescent cells release (“inflammaging”) aims to limit their harm to surrounding tissue.
Targeting precisely Frontier
Clearing only harmful senescent cells, while sparing useful ones, is an active challenge — not all senescent cells are bad.
Measuring the benefit Demonstrated
Biological-age and tissue measures aim to honestly track whether clearance actually improves health.
Cited as evidence the capability is real — not as partners or endorsers.
Universities & institutes
Academic geroscience and aging-biology research centers studying senolytics and cellular senescence.
Government & programs
National Institute on Aging (NIA, NIH) · NIH geroscience programs · ARPA-H.
Enabling science base
senolytic therapeutics · cellular-senescence biology · inflammaging research · biological-age measurement.
The technologies: senolytic drugs that selectively clear senescent cells; senomorphics that quiet the harmful signals they release; cellular-senescence biology that defines which cells to target; and biological-age measurement to test, honestly, whether clearance helps.
Reversed aging signs in animals Demonstrated in animals
Clearing senescent cells reversed multiple signs of aging and extended healthy life in animal studies — the basis for human testing.
Senolytics in human trials Clinical — trials
Senolytic drugs (such as a dasatinib-and-quercetin combination) are being tested in human trials for age-related conditions.
Not all senescence is harmful Frontier
Some senescent cells play useful roles, so clearance must be selective — a real scientific challenge.
Human benefit unproven Frontier
Whether clearance extends healthy human life is not yet proven — the central open question.
The honest challenges, held to a high bar because this field attracts hype: senolytics reversed aging signs in animals, but benefit in humans is not yet proven — trials are ongoing, not conclusive. Clearance must be selective, since some senescent cells are useful. Long-term safety must be established. And results must be measured over long timeframes. What is real: animal reversal and human trials underway. What is unproven: that clearing senescent cells extends healthy human life. We will not blur that line.
The future, fully built
A person facing the wear of age has the cells that drive decline cleared: senescent cells selectively removed, the inflammation they cause calmed, age-related decline reduced — with every claim measured honestly. Aging’s worn-out cells become something we can remove, as the evidence earns it.
The proof, for this capability
Cited as evidence the capability is real, not as partners or endorsers.
Senolytics reversed aging in animals
Clearing senescent cells reversed multiple aging signs and extended healthy life in animal studies. Stage: Demonstrated (animal).
Human trials underway
Senolytic drugs (e.g. dasatinib + quercetin) are in human trials for age-related conditions. Stage: Clinical (trials).
Selectivity & proof
Clearance must spare useful senescent cells; human healthspan benefit is not yet proven. Stage: Frontier.
Honest framing
Real organizations and studies are cited as evidence the capability is real — not as partners or endorsers. No senolytic is proven to extend healthy human life; nothing here claims one is.
Help build this future
Every signature grows the movement to make healthy longevity real — honestly — and free at the point of need.